Dipraglurant
- Generic Name
- Dipraglurant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H12FN3
- CAS Number
- 872363-17-2
- Unique Ingredient Identifier
- CV8JZR21A1
- Background
Dipraglurant has been used in trials studying the treatment of Parkinson's Disease. It is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy
- Conditions
- Dyskinesia, Drug-InducedParkinson DiseaseDyskinesias
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Addex Pharma S.A.
- Target Recruit Count
- 140
- Registration Number
- NCT05116813
- Locations
- ๐บ๐ธ
Abington Neurologic Associates, Abington, Pennsylvania, United States
๐บ๐ธThe Ohio State University Wexner Medical Center, Columbus, Ohio, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Addex Pharma S.A.
- Target Recruit Count
- 15
- Registration Number
- NCT05027997
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
- Conditions
- DyskinesiasDyskinesia, Drug-InducedParkinson Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Addex Pharma S.A.
- Target Recruit Count
- 140
- Registration Number
- NCT04857359
- Locations
- ๐บ๐ธ
Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States
๐บ๐ธSuncoast Neuroscience Associates Inc, Saint Petersburg, Florida, United States
๐บ๐ธGeodyssey Research LLC, Vero Beach, Florida, United States
PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 12
- Registration Number
- NCT02447640
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2012-07-16
- Lead Sponsor
- Addex Pharma S.A.
- Target Recruit Count
- 83
- Registration Number
- NCT01336088
- Locations
- ๐ฉ๐ช
Addex Investigator Site, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.